| Lana Maria De Souza Lawrence, MD | |
|
4701 Ogletown Stanton Rd, Ste 1109, Newark, DE 19713-2079 | |
| (302) 623-4800 | |
| (302) 623-4850 |
| Full Name | Lana Maria De Souza Lawrence |
|---|---|
| Gender | Female |
| Speciality | Radiation Oncology |
| Experience | 16 Years |
| Location | 4701 Ogletown Stanton Rd, Newark, Delaware |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225296668 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Christiana Hospital | Newark, DE | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Radiation Oncologists, Pa | 5597727693 | 11 |
| Christiana Care Health Services Inc | 9739097569 | 1248 |
| Radiation Oncologists, Pa | 5597727693 | 11 |
News Archive
Although type 1 diabetes can be controlled with insulin injections and lifestyle modifications, major advances in treating the disease have not been made in more than two decades and there remain fundamental gaps in what is understood about its causes and how to halt its progression.
Advanced Cell Technology, Inc. announced today that it is positioned to obtain significant patents relating to cellular reprogramming and the generation of induced pluripotent stem (iPS) cells. iPS cells are similar to embryonic stem (ES) cells, except they are generated from adult cells such as skin using certain reprogramming factors, without the controversial use of embryos. Although human iPS cells were first produced in 2007, ACT has been working on inducing pluripotency, with positive results, for more than a decade. The Company's efforts go back to the 1990s, providing (through existing patent filings and continuations) some of the earliest priority dates in the field.
Mutations in the genes that defend the body against cancer-related viruses and other infections may play a larger role in breast cancer than previously thought, according to a study at the University of Illinois at Chicago.
Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today introduced the Microcyn Negative-Pressure Wound Therapy Solution™ for the U.S. professional healthcare market. Within the pH ranges of 6-7.8 desired for optimum negative-pressure wound therapy, Microcyn is intended for the irrigation and management of wounds via these advanced systems.
› Verified 1 days ago
| Entity Name | Radiation Oncologists, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710917968 PECOS PAC ID: 5597727693 Enrollment ID: O20050805000534 |
News Archive
Although type 1 diabetes can be controlled with insulin injections and lifestyle modifications, major advances in treating the disease have not been made in more than two decades and there remain fundamental gaps in what is understood about its causes and how to halt its progression.
Advanced Cell Technology, Inc. announced today that it is positioned to obtain significant patents relating to cellular reprogramming and the generation of induced pluripotent stem (iPS) cells. iPS cells are similar to embryonic stem (ES) cells, except they are generated from adult cells such as skin using certain reprogramming factors, without the controversial use of embryos. Although human iPS cells were first produced in 2007, ACT has been working on inducing pluripotency, with positive results, for more than a decade. The Company's efforts go back to the 1990s, providing (through existing patent filings and continuations) some of the earliest priority dates in the field.
Mutations in the genes that defend the body against cancer-related viruses and other infections may play a larger role in breast cancer than previously thought, according to a study at the University of Illinois at Chicago.
Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today introduced the Microcyn Negative-Pressure Wound Therapy Solution™ for the U.S. professional healthcare market. Within the pH ranges of 6-7.8 desired for optimum negative-pressure wound therapy, Microcyn is intended for the irrigation and management of wounds via these advanced systems.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lana Maria De Souza Lawrence, MD Po Box 12870, Wilmington, DE 19850-2870 Ph: (302) 733-0374 | Lana Maria De Souza Lawrence, MD 4701 Ogletown Stanton Rd, Ste 1109, Newark, DE 19713-2079 Ph: (302) 623-4800 |
News Archive
Although type 1 diabetes can be controlled with insulin injections and lifestyle modifications, major advances in treating the disease have not been made in more than two decades and there remain fundamental gaps in what is understood about its causes and how to halt its progression.
Advanced Cell Technology, Inc. announced today that it is positioned to obtain significant patents relating to cellular reprogramming and the generation of induced pluripotent stem (iPS) cells. iPS cells are similar to embryonic stem (ES) cells, except they are generated from adult cells such as skin using certain reprogramming factors, without the controversial use of embryos. Although human iPS cells were first produced in 2007, ACT has been working on inducing pluripotency, with positive results, for more than a decade. The Company's efforts go back to the 1990s, providing (through existing patent filings and continuations) some of the earliest priority dates in the field.
Mutations in the genes that defend the body against cancer-related viruses and other infections may play a larger role in breast cancer than previously thought, according to a study at the University of Illinois at Chicago.
Oculus Innovative Sciences, Inc., a commercial medical technology company that designs, produces and markets safe and effective tissue care products based upon the Microcyn® Technology platform, today introduced the Microcyn Negative-Pressure Wound Therapy Solution™ for the U.S. professional healthcare market. Within the pH ranges of 6-7.8 desired for optimum negative-pressure wound therapy, Microcyn is intended for the irrigation and management of wounds via these advanced systems.
› Verified 1 days ago
Dr. Kristina Siddall, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Department Of Radiology, Newark, DE 19718 Phone: 302-733-1806 Fax: 302-733-1808 | |
Scot E. Goldberg, D.O. Radiology Medicare: Medicare Enrolled Practice Location: J24 Omega Drive, Newark, DE 19713 Phone: 302-738-9100 Fax: 302-738-9748 | |
Rabia Hasan, Radiology Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Newark, DE 19718 Phone: 302-733-1041 Fax: 302-733-1068 | |
Dr. Leonard Rosenbaum, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 4755 Ogletown Stanton Rd, Department Of Radiology, Newark, DE 19718 Phone: 302-733-1806 Fax: 302-733-1808 | |
Barbara J Albani, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown - Stanton Road, Suite 1e10, Newark, DE 19718 Phone: 302-733-1487 Fax: 302-733-1888 | |
Richard L Ward, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 100 Peoples Plz, Newark, DE 19702 Phone: 302-392-5600 Fax: 302-392-5617 | |
Sara C. Gavenonis, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 4755 Ogletown Stanton Rd, Dept Of Radiology, Christiana Care Health Services, Newark, DE 19718 Phone: 302-733-1806 |